HC Wainwright & Co. Reiterates Buy Rating on Biomea Fusion, Inc. (BMEA)

Market Context

Biomea Fusion, Inc. operates in the Healthcare sector. The stock currently trades at $0.84 with a market capitalization of $90.4M.

Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Biomea Fusion, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Biomea Fusion, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Oct 14, 2026	Citizens	Market Outperform	N/A
Oct 14, 2026	HC Wainwright & Co.	Buy	N/A
Oct 07, 2026	Brookline Capital	Buy	N/A
May 05, 2026	Citizens	Market Outperform	N/A
Apr 28, 2026	D. Boral Capital	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View BMEA Stock Page